Dataset of an energy community's generation and consumption with appliance allocation.

Energy data measured on-site from buildings can help describe the consumption behavior of end-users and can be used to examine and prove certain theorems and models, that require a large volume of data to be gathered. However, the direct extraction of this data can often be a lengthily and costly process. As a result, a dataset of a residential community was constructed based on real data, where sample consumption and photovoltaic generation profiles were attributed to 50 residential households and a public building (municipal library), a total of 51 buildings. In addition, the overall power consumption of these houses was desegregated into the consumption of 10 commonly used appliances using real energy profiles. First, several consumption and photovoltaic generation profiles, as well as a vast collection of appliance profiles, were gathered. These profiles were obtained from household readings in different locations, while the public building's profile was based on the consumption and photovoltaic production profiles of the research building GECAD. The profiles went through the process of normalization and new profiles were generated to complete the number of end-users needed. Moreover, these profiles were given a maximum consumption and production level at random before being accepted by one of the end-users. Therefore, fourteen of these households and the public building were randomly attributed with renewable solar energy. Finally, if possible, the tool created allocated, at random in previously determined intervals, the appliances' load profiles into each end-user's available consumption areas.

Update on the role of antiseptics in the management of chronic wounds with critical colonisation and/or biofilm.

Biofilms play a major role in delaying chronic wounds from healing. A wound infiltrated with biofilm, or "critically colonised" wound, may become clinically infected if the number of microbes exceeds a critical level. Chronic wound biofilms represent a significant treatment challenge by demonstrating recalcitrance towards antimicrobial agents. However, a "window of opportunity" may exist after wound debridement when biofilms are more susceptible to topical antiseptics. Here, we discuss the role of antiseptics in the management of chronic wounds and biofilm, focusing on povidone-iodine (PVP-I) in comparison with two commonly used antiseptics: polyhexanide (PHMB) and silver. This article is based on the literature reviewed during a focus group meeting on antiseptics in wound care and biofilm management, and on a PubMed search conducted in March 2020. Compared with PHMB and silver, PVP-I has a broader spectrum of antimicrobial activity, potent antibiofilm efficacy, no acquired bacterial resistance or cross-resistance, low cytotoxicity, good tolerability, and an ability to promote wound healing. PVP-I represents a viable therapeutic option in wound care and biofilm management, with the potential to treat biofilm-infiltrated, critically colonised wounds. We propose a practical algorithm to guide the management of chronic, non-healing wounds due to critical colonisation or biofilm, using PVP-I.

Addressing the challenges in antisepsis: focus on povidone iodine.

OBJECTIVES: Using antiseptics in wound care can promote healing by preventing and treating infection. However, using antiseptics can present many challenges, including issues with tolerability, inactivation by organic matter and the emergence of antimicrobial resistance/cross-resistance. This review discussed the key challenges in antisepsis, focusing on povidone-iodine (PVP-I) antiseptic. METHODS: Literature searches were conducted in PubMed, in January 2019, with a filter for the previous 5 years. Searches were based on the antimicrobial efficacy, antiseptic resistance, wound healing properties, and skin tolerability for the commonly used antiseptics PVP-I, chlorhexidine gluconate (CHG), polyhexanide (PHMB), and octenidine (OCT). Additional papers were identified based on author expertise. RESULTS: When compared with CHG, PHMB and OCT, PVP-I had a broader spectrum of antimicrobial activity against Gram-negative bacteria, actinobacteria, bacterial spores, fungi and viruses, and a similar and broad spectrum of activity against Gram-positive bacteria. PVP-I was also highly effective at eradicating bacterial biofilms, which is a vitally important consideration for wound care and infection control. Despite a long history of extensive use, no resistance or cross-resistance to PVP-I has been recorded, which is in contrast with other antiseptics. Despite previous misconceptions, it has been shown that PVP-I has low allergenic properties, low cytotoxicity and can promote wound healing through increased expression of transforming growth factor beta. CONCLUSION: With increased understanding of the importance of tackling antimicrobial resistance and bacterial biofilms in acute and chronic wound care, alongside improved understanding of the challenges of antiseptic use, PVP-I remains a promising agent for the management of antisepsis.